公开(公告)号：WO2023034115A1

公开(公告)日：2023-03-09

申请号：PCT/US2022/041502

申请日：2022-08-25

Applicant: ZOGENIX INTERNATIONAL LIMITED

Inventor： CHA, John, Chang-Eun ,  REEDER, Thaddeus, Cromwell

IPC: A61K31/137 ,  A61P25/28 ,  A61P25/00

Abstract: Methods of modifying disease progression of a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are also described herein.

公开(公告)号：WO2021247293A1

公开(公告)日：2021-12-09

申请号：PCT/US2021/034093

申请日：2021-05-25

Applicant: GLYKON TECHNOLOGIES GROUP, LLC

Inventor： CLOUATRE, Daniel E.

IPC: A61K31/225 ,  A61K47/10 ,  A61K47/12 ,  A61K31/194 ,  A61P25/16 ,  A61P3/00

Abstract: The invention relates generally to the field of medical treatment. More particularly, the invention relates to treating a patient in order to increase the amount of ketones metabolized by mitochondria. Exemplary patients include those with Alzheimer's disease and insulin resistance.

公开(公告)号：WO2021188504A1

公开(公告)日：2021-09-23

申请号：PCT/US2021/022512

申请日：2021-03-16

Applicant: FLOW PHARMA, INC. ,  RUBSAMEN, Reid M. ,  BURKHOLTZ, Scott ,  HERST, Charles V. ,  HODGE, Tom ,  WANG, Lu

Inventor： RUBSAMEN, Reid M. ,  BURKHOLTZ, Scott ,  HERST, Charles V. ,  HODGE, Tom ,  WANG, Lu

IPC: A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P11/00 ,  A61P19/02

Abstract: An injectable formulation, comprising: poly(lactic-co-glycolic (PLGA) microsphere encapsulating siltuximab, wherein microspheres are sized to release siltuximab over a period of hours, days and weeks, where the biocompatible polymer releases antibody at an absorption rate which is characterized by an absorption rate constant (Ka (h-1) in the range of (0.001 to 2.048 ) +/- 20%, or +/- 10%. or +/- 5%.. for use and treating human patients with infections. The invention includes treating patients with viral infections of SARS-Cov-2 using siltuximab.

公开(公告)号：WO2020180713A1

公开(公告)日：2020-09-10

申请号：PCT/US2020/020458

申请日：2020-02-28

Applicant: FLOW PHARMA, INC. ,  RUBSAMEN, Reid M. ,  HERST, Charles V. ,  WANG, Lu ,  BURKHOLZ, Scott R. ,  CARBACK, Richard T. ,  CIOTIOS, Serban I.

Inventor： RUBSAMEN, Reid M. ,  HERST, Charles V. ,  WANG, Lu ,  BURKHOLZ, Scott R. ,  CARBACK, Richard T. ,  CIOTIOS, Serban I.

IPC: A61K39/395 ,  C07K14/705 ,  C07K16/28 ,  C12Q1/68 ,  C12Q1/6881 ,  G01N33/569 ,  G06N3/12

Abstract: Personalized cancer vaccines are created by predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and creating a particle containing the neoantigen with the stronger predicted binding affinity. Such a predicting step includes artificial intelligence, statistical modeling, or a combination thereof. Such a particle is created by encapsulating the neoantigen with the stronger predicted binding affinity for the HLA complex of the patient in a material. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine.

公开(公告)号：WO2020014075A1

公开(公告)日：2020-01-16

申请号：PCT/US2019/040586

申请日：2019-07-03

Applicant: ZOGENIX INTERNATIONAL LIMITED ,  BOYD, Brooks M. ,  FARFEL, Gail

Inventor： BOYD, Brooks M. ,  FARFEL, Gail

IPC: A61K31/137 ,  A61P25/08 ,  G01N33/50

Abstract: Provided herein are methods of identifying a patient population as candidates for effective treatment of symptoms of epilepsy or epileptic encephalopathy with fenfluramine or a pharmaceutically acceptable salt thereof, by pre-selecting patients diagnosed with epilepsy or epileptic encephalopathy, assessing the pre-selected patients for being at risk of or exhibiting symptoms of pulmonary hypertension, treating and re-assessing the selected and treated patients for pulmonary hypertension, and identifying treated and re-assessed patients not exhibiting pulmonary hypertension as candidates for effective treatment of epilepsy or epileptic encephalopathy with fenfluramine or a pharmaceutically acceptable salt thereof.

公开(公告)号：WO2020009940A1

公开(公告)日：2020-01-09

申请号：PCT/US2019/039895

申请日：2019-06-28

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： RUBINSKY, Dan ,  RUBINSKY, Boris ,  SHAKED, Ze'ev ,  UKPAI, Gideon

IPC: A23P10/20 ,  B29C64/106 ,  B29C64/371 ,  B29C64/40 ,  B33Y10/00 ,  B33Y30/00

Abstract: A method of additive manufacturing biological matter is provided. The method includes preparing an aqueous solution, combining the aqueous solution with a thickening gent, forming the combination into a plurality of two-dimensional individual volume elements in parallel, assembling the plurality of individual volume elements in a three-dimensional array and solidifying the three-dimensional array. Methods of additive manufacturing a food product and a three-dimensional structure with aqueous solution or organic matter are also provided. A system for additively depositing elements including an aqueous solution or organic matter is also provided.

公开(公告)号：WO2019241005A1

公开(公告)日：2019-12-19

申请号：PCT/US2019/035591

申请日：2019-06-05

Applicant: ZOGENIX INTERNATIONAL LIMITED ,  MARTIN, Parthena

Inventor： MARTIN, Parthena ,  GALER, Bradley S. ,  FAINGOLD, Carl L.

IPC: A61K31/137 ,  A61K31/166 ,  A61K31/439 ,  A61K31/5375 ,  A61P11/16 ,  A61P25/08

Abstract: 5-HT receptor agonists are useful in the treatment of a variety of diseases. Provided herein are methods of treating and/or reducing the occurrence of respiratory depression caused by an opioid in a human patient or patient population using a 5-HT receptor agonist, such as, for example, a 5-HT4 agonist ( e.g ., fenfluramine). Methods of stimulating one or more 5-HT 4 receptors in the brain of a patient undergoing treatment with an opioid, wherein the patient is at risk of respiratory depression, by administering a 5-HT4 agonist ( e.g ., fenfluramine) to a subject in need thereof are provided. Pharmaceutical compositions for use in practicing the subject methods are also provided.

公开(公告)号：WO2019108770A1

公开(公告)日：2019-06-06

申请号：PCT/US2018/063025

申请日：2018-11-29

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： VITTI, Robert L. ,  BERLINER, Alyson J. ,  CHU, Karen

IPC: A61K38/17 ,  A61P27/02

Abstract: The present invention provides methods for treating or preventing diabetic retinopathy, e.g., nonproliferative diabetic retinopathy, by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of a 2mg aflibercept by intravitreal injection q8 weeks after three or five initial monthly doses (2q8) or 2 mg q16 weeks after three initial monthly doses and one 8-week interval (2q16). Moreover, the present invention provides methods for reversing or halting the progression NPDR to PDR (e.g., such that the DRSS is reduced by 2 or 3 levels) or preventing the occurrence or reoccurrence of a vision threatening complication by administering aflibercept according to the dosing regimens set forth herein.

公开(公告)号：WO2018085792A1

公开(公告)日：2018-05-11

申请号：PCT/US2017/060243

申请日：2017-11-06

Applicant: BIOMEDISTEM, LLC ,  KILBANK, Daniel

Inventor： KILBANK, Daniel

IPC: C12N5/00 ,  C12N15/00

Abstract: Compositions and methods are provided for the generation of highly potent conditioned stem (Epinul) cells from adult somatic cells or tissues. Such conditioned stem cells are capable of generating all the cell lineages of any tissue or organ. Uses and compositions of the conditioned stem cells are also disclosed.

Abstract translation: 提供组合物和方法用于从成体体细胞或组织产生高效力条件化干（Epinul）细胞。 这种条件化干细胞能够产生任何组织或器官的所有细胞谱系。 还公开了条件化干细胞的用途和组成。

公开(公告)号：WO2017123315A3

公开(公告)日：2017-07-20

申请号：PCT/US2016/060824

申请日：2016-11-07

Applicant: ARADIGM CORPORATION

Inventor： CIPOLLA, David C. ,  GONDA, Igor

IPC: A61K9/00 ,  A61K9/12 ,  A61K9/127 ,  A61K9/133 ,  A61K9/19 ,  A61K31/18 ,  A61K31/245 ,  A61K31/395 ,  A61K31/49 ,  A61K31/496 ,  A61K31/65

Abstract: A formulation is disclosed which is comprised of a first solvent having a first active ingredient dissolved therein a plurality of microenvironments dispersed in the first solvent, the microenvironment being comprised of a spherical shell having a diameter in a range of 0.5 micron to 100 microns, the shell comprising an internal volume comprising a second solvent having a second active ingredient dissolved therein and nanocrystals of the second active ingredient.